GSK's Benlysta (belimumab- IV) Receives EC's Approvals as the First Biologic to Treat Lupus in Children
Shots:
- The EC’s approval is based on PLUTO study assessing Benlysta (10 mg/kg IV) + SoC vs PBO + SoC in 93 children aged 5 – 11yrs. and 12 – 17yrs. with systemic lupus erythematosus for 1yr. The EC’s approval follows recent approval in the US & Japan
- The PLUTO study result: improvement in disease activity as assessed by SLE responder index response rate (52.8% vs 43.6%); patients with at least one AE and a serious AEs (79.2% and 17.0% vs 82.5% and 35.0%); PK & benefit-risk profile is consistent with adult SLE
- Benlysta is mAb targeting BLyS and has received approval for adults with SLE in the EU as an IV formulation in Jul’2011 and SC formulation in Nov’2017
Click here to read full press release/ article |
Ref: GSK | Image: GSK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com